Blog

Horizon Aircraft hosted Brigadier General Brendan Cook, RCAF Director General Space, Combat and Support, for a briefing on the Cavorite X7 and its potential Defence applications

LINDSAY, ONTARIO / ACCESS Newswire / November 6, 2025 / New Horizon Aircraft Ltd. (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one the world’s first hybrid eVTOL (electric Vertical Take-Off and Landing) aircraft, welcomed Brigadier General Brendan Cook, Royal Canadian Air Force (RCAF) Director General Space, Combat and Support, to its Lindsay, Ontario hangar for an exclusive tour and briefing on the Company’s hybrid eVTOL, the Cavorite X7.

During the visit, BGen Cook met with Horizon Aircraft’s leadership team, toured the facility, and received a detailed demonstration of the Cavorite X7’s hybrid-electric architecture and versatile design.

“I’ve seen some really unique technologies here that I think have a solid position in the Defence market over time,” said BGen Cook. “It’s great to see Canadian innovation and industry putting forward leading-edge aerospace products. From remotely piloted aircraft to vertical lift capabilities, the applications for this technology in the Canadian Armed Forces are wide-ranging, from contested logistics to maritime operations and anti-submarine warfare.”

BGen Cook also noted the potential for NATO collaboration, citing opportunities for Canadian industry to shape and contribute to evolving allied defence requirements.

Horizon Aircraft Co-Founder and CEO, Brandon Robinson, said, “It was an honour to host BGen Cook and share the progress we’ve made with the Cavorite X7. His visit underscores the growing recognition of Canadian aerospace innovation, and we believe our technology is well positioned for future defence applications in Canada and with our allies worldwide.”

The Cavorite X7 has been engineered with defence and dual-use applications in mind, offering potential roles in:

• Contested logistics and cargo delivery;

• Medical evacuation (MEDEVAC) and covert insertion;

• Remotely Piloted Aircraft Systems (RPAS) and loyal wingman missions; and

• Advanced surveillance and electronic power support, enabled by its onboard hybrid electrical capacity.

With the Cavorite X7, Horizon Aircraft continues to position Canada as a leader in aerospace technology, advancing solutions that align with the modern defence needs of the Canadian Armed Forces and allied partners.

For more information about Horizon Aircraft, please see the Company’s website or watch its innovative technology in action on the Company’s YouTube channel.

About Horizon Aircraft

Horizon Aircraft (NASDAQ: HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid eVTOL designed to fly most of its mission exactly like a normal aircraft while offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety, performance, and utility. Horizon Aircraft intends to successfully complete testing and certification of its Cavorite X7 eVTOL and then scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

For further information, visit:

Website www.horizonaircraft.com
LinkedIn https://www.linkedin.com/company/horizon-aircraft-inc

For further information, contact:

Investors:
Matt Chesler, CFA
FNK IR LLC
(646) 809-2183
HOVR@fnkir.com

Media:
Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “target,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements herein include, but are not limited to, statements relating to the targeted readiness of the full-scale hybrid Cavorite X7 eVTOL prototype for initial testing, development priorities and technical milestones; funding and liquidity sufficiency and runway; certification and testing plans; and potential production, partnership, supply chain and market opportunities.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Horizon Aircraft competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Horizon Aircraft will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) the lack of useful financial information for an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Horizon Aircraft’s industry and market size; (v) financial condition and performance of Horizon Aircraft, including the condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Horizon Aircraft; (vi) Horizon Aircraft’s ability to develop, certify, and manufacture an aircraft that meets its performance expectations; (vii) successful completion of testing and certification of Horizon Aircraft’s Cavorite X7 eVTOL; (viii) the targeted future production of Horizon Aircraft’s Cavorite X7 aircraft; and (ix) other factors detailed by us in the Company’s public filings with the Securities and Exchange Commission (“SEC”) and under the Company’s profile on sedarplus.ca, including the disclosures under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2025, filed with the SEC and filed under the Company’s profile on sedarplus.ca on August 22, 2025. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made.

Readers are cautioned not to put undue reliance on forward-looking statements, and while the Company may elect to update these forward-looking statements at some point in the future, it assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law. Horizon Aircraft does not give any assurance that Horizon Aircraft will achieve its expectations.

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire

LSEG Announces Strategic Partnership with Nasdaq^® to Deliver Enhanced Private Markets Data

LONDON, UK / ACCESS Newswire / November 6, 2025 / LSEG today announced a strategic partnership with Nasdaq to distribute institutional-grade private markets intelligence through LSEG’s Workspace and Datafeeds.

Under the agreement, LSEG will license Nasdaq eVestment™ private markets datasets including Market Lens insights, hedge fund insights and Limited Partner (LP) intelligence. It will also include limited exclusive distribution of Nasdaq’s private market datasets, private fund benchmarks, and deal-level benchmarks. Nasdaq’s datasets will be integrated into LSEG’s ecosystem, expanding transparency and decision-making capabilities across the private investment landscape.

The partnership builds on LSEG’s recent launch of the UK’s first Private Securities Market in September 2025, reinforcing its commitment to expanding private market infrastructure and data coverage. For Nasdaq, the collaboration reflects its broader strategy to embed transparency and liquidity into private markets, transforming how intelligence is accessed and how data is delivered across the investment ecosystem.

Gianluca Biagini, Group Co-Head, Data & Analytics, LSEG, said:

“This partnership underscores our commitment to delivering unparalleled private markets intelligence. By integrating Nasdaq’s datasets with LSEG’s existing capabilities, we are creating a best-in-class solution that serves the entire private market ecosystem. Together, we will provide richer content, deeper data coverage, and tools that empower our clients to make informed decisions.”

Oliver Albers, Executive Vice President and Chief Product Officer, Capital Access Platforms, Nasdaq, said:

“Through this integration, we are extending the reach of Nasdaq’s private market data to deliver greater transparency and more actionable intelligence across the global investment landscape. This partnership empowers investors with seamless access to critical insights in existing workflow solutions to drive better-informed decisions and market efficiency.”

The combined offering brings together LSEG’s editorial and transactional data on private companies with Nasdaq’s fund performance and LP insights, creating a comprehensive solution for General Partners (GP), Limited Partners (LP), and advisors. It streamlines critical workflows across investment targeting, deal execution, fundraising, and portfolio optimisation, enabling more informed decisions and efficient capital deployment.

Contacts

LSEG Press Office

Lucie Holloway / Tarek Fleihan – External Communications
+44 (0)20 7797 1222
newsroom@lseg.com

About LSEG

LSEG is a leading global financial markets infrastructure and data provider, playing a vital social and economic role in the world’s financial system. With our open approach, trusted expertise and global scale, we enable the sustainable growth and stability of our customers and their communities. We are dedicated partners with extensive experience, deep knowledge and a worldwide presence in data and analytics; indices; capital formation; and trade execution, clearing and risk management across multiple asset classes. LSEG is headquartered in the United Kingdom, with significant operations in 65 countries across EMEA, North America, Latin America and Asia Pacific. We employ over 26,000 people globally, more than half located in Asia Pacific. LSEG’s ticker symbol is LSEG.

© 2025 Nasdaq, Inc. Nasdaq® and Nasdaq eVestment™ are trademarks of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq eVestment, a business of Nasdaq, Inc. and certain of its subsidiaries (collectively, “Nasdaq”), for informational purposes only. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. This information is not directed or intended for distribution to, or use by, any citizen or resident of, or otherwise located in, any jurisdiction where such distribution or use would be contrary to any law or regulation or which would subject Nasdaq to any registration or licensing requirements or any other liability within such jurisdiction. By reviewing this material, you acknowledge that neither Nasdaq nor any of its third-party providers shall under any circumstance be liable for any lost profits or lost opportunity, direct, indirect, special, consequential, incidental, or punitive damages whatsoever, even if Nasdaq or its third-party providers have been advised of the possibility of such damages.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: London Stock Exchange Group PLC

View the original press release on ACCESS Newswire

ORLANDO, FLORIDA / ACCESS Newswire / November 6, 2025 / Epique Realty, one of the fastest-growing brokerages in history, gathered its extraordinary leaders for the second annual Leadership Retreat, kicking off with a vibrant Welcome Party at Margaritaville Orlando on November 5. The multi-day event set a high-energy tone, bringing together the company’s leaders for a focused blend of high-level strategy, deep connection, and celebration of another record-breaking year.

The core of the retreat on Thursday featured a full day of intensive workshops and learning, headlined by Keynote Speaker, Co-Founder of Haven Real Estate Group, Performance Coach, and Author Robert Henry, who delivered powerful insights on leading through complexity and building operational resilience at scale. Additional sessions, led by industry heavyweights and Epique’s internal experts, focused on actionable playbooks for growth enablement, recruiting velocity, advanced agent training systems, and fostering a culture of high performance.

Epique’s three exceptional Co-Founders were on hand to provide context for the event’s mission and the company’s forward momentum.

“Support and accountability travel together,” said Janice Delcid, Co-Founder and CFO. “Our leaders are leaving Orlando with concrete; strategic playbooks they can deploy on Monday to create immediate value for their agents.”

“Inclusion scales outcomes,” added Christopher Miller, Co-Founder and COO. “The best ideas in our network come from this exact kind of collaboration, across states, countries, and roles. You can feel the momentum and excitement for our shared vision in every single session.”

In a signature move underscoring Epique’s “people-first” culture, the brokerage is closing the event by treating over 600 leaders and their family members to a day at Walt Disney World on Friday. This tangible investment in shared experience highlights the company’s commitment to building a true community and celebrating its collective success as a family.

“Leadership is a practice, not a title,” concluded Joshua Miller, CEO and Co-Founder. “This retreat is about equipping our leaders to build durable value for agents, clients, and communities. We are aligning on our executional clarity for 2026 while ensuring our unique, agent-centric culture remains front and center in everything we do.”

Event Highlights

• Welcome Party: Margaritaville Orlando, November 5

• Conference Day: November 6, featuring keynote Robert Henry, and additional sessions were led by Sam Rodriguez, Brooke Broady, Lee Garland, Rob Stein, and a roster of Epique Realty leaders, covering growth enablement, recruiting velocity, training systems, and culture-driven performance.

• Family Day at Disney: November 7, 600 tickets provided for leaders and their families

About Epique Realty

As the industry’s first AI-certified brokerage, Epique Realty is one of the fastest-growing, agent-owned real estate brokerages. Shaping the future of real estate, Epique now operates in all fifty states with over 4,000 agents, and with Canada on-board, global expansion is underway. Its revolutionary agent-first model provides over 80 unheard of free phenomenal benefits with a proprietary AI platform (Epique.ai), and a culture of radical generosity. Led by its visionary co-founders, Epique is harnessing technology to build a more equitable, empowered, and successful future for real estate professionals. #BeEpique

MEDIA
Barbara Simpson | PR and Communications
281-773-7842 | Barbara@EpiqueRealty.com

https://www.instagram.com/epiquerealty/
https://www.facebook.com/epiquerealty
https://www.linkedin.com/company/epique-realty/mycompany/
https://www.youtube.com/@epiquerealty

#BeEpique #EpiqueLeadership #Leadership #CompanyCulture #RealEstateBroker #PeopleFirst #DisneyWorld #TheEpiqueWay #LetsChangeEverything

SOURCE: Epique Realty

View the original press release on ACCESS Newswire

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September

Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67^th Annual American Society of Hematology (ASH) meeting in December

First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist

IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o

Oral hepcidin development candidate expected to be nominated by year end

Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028

NEWARK, CA / ACCESS Newswire / November 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

“2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs,” said Dinesh V. Patel, Ph.D., the Company’s President and CEO. “In addition to the NDA and EMA submissions for icotrokinra for psoriasis, we are pleased to see our partner Johnson and Johnson expand the ICONIC program into additional IL-23 pathway relevant and validated I&I indications, namely psoriatic arthritis, ulcerative colitis, and Crohn’s disease. We, along with our partner Takeda, eagerly await the presentation of the rusfertide 52-week VERIFY data at ASH in December and the NDA filing for rusfertide by year end.”

“As icotrokinra and rusfertide move towards potential NDA approval and commercialization in 2026, we shift our attention to the next phase of assets emerging from our validated discovery and development platform. We are pleased to report that the first subject in the Phase 1 trial of oral IL-17 antagonist, PN-881, is dosed. Additionally, the oral and subcutaneous triple GLP/GIP/GCG agonists, PN-477o and PN-477sc, are progressing through

IND-enabling studies as planned, and we remain on track to nominate a development candidate from the oral hepcidin program by year end. I am very proud of the consistent innovation and execution capabilities of the Protagonist team,” Patel said.

Third Quarter 2025 Recent Developments and Upcoming Milestones

Icotrokinra: Oral IL-23 Receptor Antagonist

• In November, publications of ICONIC-LEAD data through Week 24 (available here) and ICONIC-TOTAL data through Week 16 (available here) were published in the New England Journal of Medicine, and the NEJM Evidence, respectively.

• On October 27th, the Company and Johnson and Johnson announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra in adults with moderately to severely active ulcerative colitis (UC) at the 2025 ACG Annual Scientific Meeting. I cotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo.

• On October 26 ^th , new long-term 52-week data from the Phase 3 ICONIC-TOTAL study, was presented at the 2025 Fall Clinical Dermatology Conference. The data show icotrokinra demonstrated high and durable rates of site-specific psoriasis clearance affecting these high-impact and difficult-to-treat areas of the body.

• On October 7th, the Company and its partner JNJ announced Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra in adults with moderately to severely active UC at United European Gastroenterology Week (UEGW) 2025.

• On September 17th, new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies, which assessed the superiority of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis (PsO), was presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. Additionally, new long-term 52-week data from the Phase 3 ICONIC-LEAD study investigating icotrokinra in adults and pediatric patients 12 years of age and older (adolescents) with moderate to severe PsO was presented as a late-breaking abstract at EADV.

• On September 11th, the Company announced the submission of an application to the European Medicines Agency (EMA) by JNJ seeking the first approval of icotrokinra for the treatment of adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe PsO.

• On July 21st, the Company announced submission of a New Drug Application (NDA) to the U.S. FDA by JNJ seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate to severe PsO.

Rusfertide: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV) and Other Blood Disorders

• Clinical data on rusfertide in PV, including the Phase 3 VERIFY study, are the focus of four presentations planned at the 67 ^th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida from December 6-9, 2025. This includes an oral presentation of the durability of response and safety results through week 52 from the VERIFY study.

• On August 25th, the Company and its partner Takeda Pharmaceuticals announced rusfertide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of erythrocytosis in patients with PV.

• Rusfertide U.S. NDA filing for treatment of patients with PV, by partner Takeda Pharmaceuticals, is expected in Q4 of this year.

Discovery and Development Pipeline

• The first human subject has been dosed in the Phase 1 trial ( NCT07153146 ) of PN-881, a first-in-class oral IL-17 peptide antagonist, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants.

• The triple GLP/GIP/GCG agonists PN-477sc and PN-477o are progressing through IND-enabling studies with clinical study initiation of PN-477sc anticipated by mid-2026, and initiation of PN-477o anticipated in the second half of 2026.

• The Company plans to nominate a development candidate ready for IND-enabling studies from the oral hepcidin program by year end.

Third Quarter 2025 Financial Results

• Cash, Cash Equivalents and Marketable Securities : Cash, cash equivalents and marketable securities as of September 30, 2025, were $678.8 million as compared to $559.2 million as of December 31, 2024.

• License and Collaboration Revenue :

  • License and collaboration revenue was $4.7 million for both the three months ended 2025 and 2024 and was comprised of development services we provided under the Takeda collaboration agreement.

  • License and collaboration revenue of $38.6 million for the nine months ended September 30, 2025 was comprised of (i) proportional recognition of a $25 million milestone earned from Takeda in Q1 25, and (ii) development services we provided during the period. License and collaboration revenue of $263.8 million for the nine months ended September 30, 2024 included (i) $254.1 million of the $300.0 million initial transaction price for the Takeda collaboration agreement allocated to the rusfertide license upon effectiveness of the agreement, and (ii) development services we provided during the period.

• Research and Development (“R&D”) Expenses : Increased by $4.0 million and $9.7 million for the three and nine months ended September 30, 2025, respectively, from the prior year periods. The increases were primarily due to increases in drug discovery and pre-clinical research expenses.

• General and Administrative (“G&A”) Expenses : Increased by $1.0 million for the three months ended September 30, 2025, from the prior year period primarily due to increases in professional services. The decrease of $1.1 million in G&A expenses for the nine months ended September 30, 2025, from the prior year period was primarily due to $4.6 million in one-time advisory and legal fees related to the Takeda collaboration in Q1 24, partially offset by increases in personnel-related expenses and professional services.

• Net Income (Loss) : Net loss was ($39.3) million, or ($0.62) per basic and diluted share, for the three months ended September 30, 2025, as compared to a net loss of ($33.2) million, or ($0.54) per basic and diluted share, for the three months ended September 30, 2024. Net loss was ($85.8) million, or ($1.35) per basic and diluted share, for the nine months ended September 30, 2025, as compared to net income of $143.5 million, or $2.34 per basic share and $2.22 per diluted share, for the nine months ended September 30, 2024.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra and PN-881, and expectations regarding the icotrokinra and PN-881 development programs. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands except share and per share data)

(1) Amount includes non-cash stock-based compensation expense.

Stock-based Compensation
(Unaudited, in thousands)

PROTAGONIST THERAPEUTICS, INC.
Selected Condensed Consolidated Balance Sheet Data
(Unaudited, In thousands)

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / There’s a difference between saying and showing. Between talking about change and proving it happened. For decades, the sustainability movement has been powered by optimism, slogans, and moral urgency. But somewhere along the way, the language of progress got tangled in the politics of promises. SMX (NASDAQ:SMX) has stepped in to take the conversation to the next level. And it only requires a single word to describe how: PROOF.

When Rolling Stone declared that plastic promises are dead and proof is the new flex, it didn’t sound like just another environmental feature – it felt like a reckoning. The magazine that spent half a century defining culture had just defined the next era of commerce. Proof, not pledges, is now the currency of trust.

And that shift isn’t isolated to one outlet. From USA Today to The Straits Times, Morning Honey, OPIS, and The Los Angeles Tribune, a global media chorus is aligning on a single theme: SMX isn’t selling sustainability. It’s verifying it with PROOF.

Proof Has Replaced Faith

SMX’s molecular marking technology operates like a truth serum for the material world. It embeds a digital memory inside plastics, rubber, textiles, metals, and electronics, giving each item a verifiable identity that stays intact through recycling, reuse, and resale. That means every piece of matter – from a soda bottle to a smartphone component – can now tell its own story, backed by science.

The result is a circular economy that no longer runs on declarations or audits. It runs on data. SMX’s technology makes it possible to know, not assume, where a product came from, how it was made, and whether it truly re-entered the supply chain. It’s sustainability without the guesswork – a blueprint for measurable accountability.

USA Today captured this transformation in plain language: the global supply chain is being rebuilt around verifiable data. Every shipment, every material, every recycled input can now carry its own identity. That shift doesn’t just make reporting cleaner; it eliminates the loopholes that once allowed greenwashing to thrive. For corporations, the new reality is simple – accountability is no longer optional. It’s built in.

From Policy to Pop Culture

The validation isn’t just industrial – it’s international. The Straits Times spotlighted Singapore’s national framework for a plastics passport, a program developed in collaboration with A*STAR and powered by SMX’s molecular markers. The system lets products carry digital proof of origin and composition, extending the lifespan of materials and reshaping how recycling is tracked across ASEAN.

Meanwhile, OPIS covered SMX’s work in Asia-Pacific, adding to the value of its partnerships with CARTIF in Spain and CETI in France, two of the region’s leading innovation hubs. CARTIF is using SMX’s technology to help European industries meet new circular-economy reporting mandates, while CETI is embedding molecular IDs into fibers and fabrics, turning recycled-textile claims into verifiable data points. Sourcing Journal even followed SMX’s trail into luxury fashion, where its molecular markers are being used in lambskin and leather to validate ethical sourcing.

In Austria, REDWAVE is bringing the technology to the factory floor, integrating SMX markers into its industrial sorters to verify recycled materials in real time. In the United States, Tradepro is closing the loop by distributing certified recycled resin that carries SMX’s proof-of-signature to manufacturers under strict compliance targets.

Even the gold standard is being rewritten. Singapore-based Goldstrom is deploying SMX’s molecular marker to give precious metals a permanent digital identity, allowing banks, refiners, and traders to verify authenticity across their entire supply chain. It’s an unprecedented step for the metals market – proof where trust once relied on stamps and paper trails.

Together, these six 2025 partnerships – A*STAR, CETI, CARTIF, REDWAVE, Tradepro, and Goldstrom – form the world’s first cross-sector network of verified commerce. Proof isn’t siloed anymore; it’s global. Morning Honey captured that cultural shift, showing how SMX’s traceability technology connects sustainability, consumer fairness, and global trade. And The Los Angeles Tribune distilled the financial impact into one line: “Carbon Credits Had Their Day.” Their replacement? SMX’s Plastic Cycle Token (PCT), a blockchain-backed proof instrument that turns verified recycled content into a tradable digital asset.

The Market Has Spoken

All told, proof isn’t a slogan anymore. It’s infrastructure. It links regulation, reputation, and revenue into a single, measurable framework. Governments and regulators see SMX as the enforcement layer that sustainability has been missing. Brands see it as the technology that transforms compliance from a cost center into a competitive advantage. Investors see a platform with expanding global relevance, capable of tracing not only waste but value itself.

The world has grown skeptical of promises. But proof – measurable, verifiable, permanent proof – has value again. SMX gave it form. It gave it structure. And as headlines from Rolling Stone to USA Today to OPIS make clear, it gave it a future.

Because in the end, progress doesn’t need another promise. It needs proof. And that’s precisely what SMX was built to deliver.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

New HIPPA-Compliant AI technology for Contract Modeling and Variance Analysis to Revolutionize Hospital Revenue Cycle Optimization

WOODSTOCK, GA / ACCESS Newswire / November 6, 2025 / For rural hospitals operating on the thinnest of margins, collecting every dollar earned, as expected and on time, can be the difference between sustainability or eventual closure. But the burden and complexity of securing hospital revenue – dealing with denials and underpayments – can often be more than a community hospital with limited resources can manage alone.

SlicedHealth, a technology provider committed to strengthening rural and community hospitals, recently launched SlicedIQ, an AI-powered solution that supports rural hospitals by helping your team easily identify and correct roadblocks to an optimal revenue cycle. This transformative AI technology, SlicedIQ, paired with SlicedHealth’s contract modeling core platform and the variance analysis module, allows rural hospitals to dig even deeper and get relevant advice and assistance.

The combination of the platform’s real-time data, paired with the SlicedIQ [assistant], allows hospitals to easily and routinely uncover hidden underpayments, strengthen their denial management strategies, and have better insight into contracts, allowing for better-informed decisions. Plus, it happens within moments, not weeks or months, while staying HIPPA-compliant, something publicly available LLMs such as ChatGPT and other AI tools cannot – even while in “privacy mode.”

SlicedIQ, bundled with Sliced Health’s existing Contract Modeling platform and Variance Analysis module, takes the burden off staff, offering a robust HIPPA-compliant revenue optimization system. The key features of SlicedIQ include:

SlicedIQ- + Contract Modeling: In addition to SlicedHealth’s existing contract modeling capabilities, SlicedIQ uses AI to analyze contracts and resources, deliver detailed summaries with actionable recommendations, and provide an interactive way to ask specific questions based on accurate, contract-driven insights. For instance, you can ask real-time, highly specific questions about your contracts, such as:

• “What are my per diem rates?”: Instantly see contracted rates across multiple payers.

• “What are my contract terms?”: Get clear, clause-level breakdowns of reimbursement rules.

• “Are there any carve-outs?”: Identify special payment provisions (e.g., high-cost drugs, implants).

SlicedIQ + Variance Analysis: This new AI-powered technology allows you to go deeper into payment discrepancies and denials, enhancing the Variance Analysis platform for faster, better, evidence-based decisions by:

• Surfacing underpayments, denials, and other relevant details instantly

• Explaining what happened and why

• Guiding staff with actionable next steps

Examples of what you can now do with SlicedIQ Variance Analysis include asking questions like:

• “How should we appeal?”: Receive step-by-step guidance tailored to denial codes and payer rules.

• “Should there be any modifiers?”: Confirm if correct coding modifiers are missing or misapplied.

• “Does the charge match the diagnosis?”: Validate coding alignment to prevent denials and underpayments.

• “Why did this claim get denied?”: Explain the reason for a denial.

Analyze  Compile  Send

SlicedIQ’s analysis sets hospitals up for revenue cycle success, freeing staff time, so they have the tools they need to take the next steps for recovery: compile the required data, then submit to the payer.

Ensuring Seamless Rollout, Ongoing Support

SlicedHealth knows if new technology platforms aren’t fully adopted, they’re not delivering value. With this in mind, a robust training program with SlicedHealth staff ensures a seamless launch and monthly check-in success calls deliver ongoing guidance in revenue cycle management to sustain performance. This allows organizations to maximize revenue cycle efficiency and strengthens financial health – quickly and without a new workload for staff or the need for additional staff. Coming soon: Our development team will continue to evolve SlicedIQ with a product roadmap showing new features in the first quarter of 2026.

About SlicedHealth

SlicedHealth brings clarity and control to the revenue cycle for health systems, community hospitals, and specialty practices. Grounded in hands-on support and built on a rules-based foundation, our platform equips hospital CEOs and CFOs with the tools they need to optimize contract performance, streamline operations without additional staff, and maximize revenue recovery. Our next-generation contract management platform delivers real-time visibility into hospital payer contracts and revenue cycle performance. Driven by SlicedIQ, our AI-powered engine that provides detailed, easy-to-use insights for contract modeling and variance analysis, the SlicedHealth platform automates better decisions across the entire revenue cycle. From claim estimation and business intelligence to a robust price transparency module built for compliance, SlicedHealth helps all hospital leaders recover revenue lost to denials and underpayments. Learn more at https://slicedhealth.com

Contact Information:

SlicedHealth
(888) 290-1298
info@SlicedHealth.com

SOURCE: SlicedHealth

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America’s leading business television and multi-platform media brands, today announced a comprehensive media partnership with Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence company developing cancer medicines with multiple clinical-stage programs.

The collaboration includes a full-year series of national TV interviews, commercial campaigns, earned media placements, and iconic billboard exposure across New York City’s Financial District and Times Square. The partnership will also integrate non-deal roadshow coverage, bringing Lantern Pharma’s story directly to institutional and accredited investor audiences across key U.S. markets.

Lantern Pharma will be featured on New to The Street’s nationally syndicated broadcasts airing on Bloomberg Television and Fox Business Network as sponsored programming, alongside coverage across the show’s digital, social, and outdoor media platforms.

Vince Caruso, Founder and CEO of New to The Street

“Lantern Pharma represents exactly the kind of innovation our platform was built to spotlight – breakthrough technology with the potential to reshape an entire industry,” said Vince Caruso, Founder and CEO of New to The Street. “We’re excited to bring their AI-driven oncology pipeline to millions of viewers through our broadcast, digital, and outdoor channels, and to help position Lantern Pharma as one of the most closely watched biotech growth stories of the year.”

Panna Sharma, CEO and President of Lantern Pharma Inc. (NASDAQ: LTRN)

“Partnering with New to The Street provides Lantern with a powerful collaborator and multiple avenues to reach investors, partners, and the broader public with our mission to transform cancer drug development through AI and data-driven insights,” said Panna Sharma, CEO of Lantern Pharma. “This aligns with our goal to expand awareness of AI our platform, our drug pipeline, and our commitment to accelerating hope for cancer patients worldwide.”

About Lantern Pharma (NASDAQ:LTRN)

Lantern Pharma (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company innovating the future of oncology by applying proprietary artificial intelligence and machine learning platforms to rapidly discover, develop, and personalize cancer therapies. The company’s RADR® platform leverages large-scale data analytics to identify novel targets, optimize drug design, and reduce development timelines.

For more information, visit www.lanternpharma.com.

About New to The Street

New to The Street is one of the longest-running U.S. and international business television brands featuring public and private companies on Bloomberg Television and Fox Business Network as sponsored programming. The platform combines long-form TV interviews, earned media, digital distribution, and outdoor billboard exposure to deliver predictable, measurable visibility for innovative companies worldwide.

Learn more at www.newtothestreet.com.

Media Contact:

Monica Brennan
New to The Street
Monica@NewToTheStreet.com

SOURCE: New to The Street

View the original press release on ACCESS Newswire

SiteLabs is a Portfolio Company of Boomerang Ventures

INDIANAPOLIS, IN / ACCESS Newswire / November 6, 2025 / Boomerang Ventures, a leading digital health tech-focused venture studio and fund, has invested $1 million as the lead investor of SiteLabs‘ $2 million Seed Round. SiteLabs is a portfolio company redefining access to care by transforming independent pharmacies into neighborhood hubs for preventive screenings and clinical research.

This seed investment includes follow-on investments from strategic partners the Labcorp Venture Fund and SC Launch, Inc. and sends a strong signal that SiteLabs is building something special – a scalable model for redesigning how communities access preventive care and research. Paired with Boomerang Ventures’ strategic support, the investment enables SiteLabs to scale its turnkey platform that empowers pharmacies to deliver affordable diagnostics, connect patients to clinical trials, and strengthen local businesses while improving health outcomes for underserved populations.

“Independent pharmacies are an untapped infrastructure for improving healthcare access in America,” said Darren Schaupp, CEO of SiteLabs. “They know their communities, see patients regularly, and can close critical gaps in preventive care and research recruitment – if we give them the right tools and partnerships. SiteLabs is empowering a new front door to healthcare for 100 million people, one neighborhood pharmacy at a time.”

Addressing Critical Healthcare Gaps

SiteLabs was founded on Schaupp’s decades of experience in global community health, where he saw firsthand how pharmacies served as the first line of care in regions with limited medical infrastructure. That perspective inspired the company’s mission in the U.S., where physician shortages and rising rates of chronic disease leave millions without timely preventive care.

The SiteLabs model tackles three pressing challenges:

1. Preventive Care Gaps – Patients skip routine screenings due to cost, distance, or lack of a primary care provider.

2. Limited Patient Engagement – Health systems and pharmaceutical companies struggle to reach at-risk patients and diversify clinical trial participation.

3. Pharmacy Financial Strain – Shrinking reimbursement rates and other pressures threaten the survival of independent pharmacies.

By equipping pharmacies with screening technology, trial recruitment workflows, and partner integrations, SiteLabs bridges these gaps with scalable, community-driven solutions.

Early Traction and Market Opportunity

The opportunity is vast: more than 60,000 community pharmacies nationwide reach nearly 90% of Americans within a five-mile radius of their homes. SiteLabs’ early pilots demonstrate the power of this model – just six pharmacies completed over 6,300 preventive screenings in a short time frame, both accelerating trial enrollment and reaching more diverse patient populations.

“SiteLabs’ approach demonstrates how innovation can solve for access, equity, and outcomes all at once,” said Oscar Moralez, Founder and Managing Partner of Boomerang Ventures. “We’re proud to partner with Darren and his team to bring forward a model that benefits patients, pharmacies, and the broader healthcare system.”

Looking Ahead

With Boomerang Ventures’ backing, SiteLabs is focused on scaling from pilot sites to hundreds of pharmacies nationwide over the next 12 to 18 months. Key priorities include integrating with major pharmacy management systems, expanding partnerships with payers and sponsors, and refining platform economics to ensure sustainable benefits across stakeholders.

“Our goal is to empower local pharmacies to become a trusted access point for preventive care and research,” added Schaupp. “By aligning the incentives of patients, pharmacies, and healthcare stakeholders, we can create healthier communities and a stronger healthcare system.”

About Boomerang Ventures

Founded in 2019, Boomerang Ventures is a venture capital firm focused on early growth-stage connected health technology companies. Leveraging a combination studio and venture fund, Boomerang provides the collaborative direction, deep industry expertise, and continuum of support founders need to take their innovations from ideation to market. Boomerang believes that better patient care begins with identifying and solving the biggest challenges in healthcare. Boomerang Ventures is proudly and strategically based in Indianapolis, where the healthcare and entrepreneurial business climate is a thriving community ripe with opportunities. With a secure niche at the intersection of health technology, studio-fund synchronization, and the Midwest, Boomerang differentiates itself from the competition. Boomerang Ventures is Healthcare Innovation, Reimagined. For more information, visit Boomerang.vc.

About SiteLabs

SiteLabs, Inc., headquartered near Clemson, South Carolina, is a health technology startup transforming independent pharmacies into community-based hubs for preventive care and clinical research. Its point-of-care platform enables pharmacies to deliver screenings for diabetes, heart disease, hypertension, cancer, and other conditions-increasing access, lowering costs, and improving outcomes for patients who need them most. By equipping pharmacies with technology to provide diagnostics, connect patients to clinical trials, and generate new revenue streams, SiteLabs strengthens local businesses while advancing population health. The company’s team brings together expertise in pharmacy, healthcare, marketing, and technology, united by a mission to support independent pharmacies and close critical gaps in care. For more information, visit sitelabsglobal.com.

# # #

Media Contacts:
Audra Wait | Wait & Co. on behalf of Boomerang Ventures
audra@waitandco.com | 615-504-8812

SOURCE: Boomerang Ventures

View the original press release on ACCESS Newswire

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / November 6, 2025 / Goldgroup Mining Inc. (“Goldgroup” or the “Company”) (TSXV:GGA)(OTCQX:GGAZF) is pleased to announce that it has filed an updated NI 43-101 technical report on the Cerro Prieto gold project located in Sonora State, Mexico. The report is entitled “Cerro Prieto Project, Heap Leach Project, Magdalena de Kino, State of Sonora, Mexico” with an effective date of April 4, 2025 (referred to herein as the “Report”). The Report, prepared by Rodrigo R Carneiro MSc, QP, SME Registered Member, José Antonio Olmedo MSc, P. Eng. Geo, QP, SME Registered Member and Cristian Garcia, P. Eng., QP, Registered at Engineers and Geoscientists of British Columbia and independent of the Company. The Report is available for viewing on Sedar+.

The Report provides independent assessment of the Mineral Resources Estimates of the Esperanzas Deposit within the Cerro Prieto Mine, which includes the La Esperanza and Nueva Esperanza contiguous zones. The Company owns 100% of the 6,980 hectares of mining concessions and has been in production since 2013. Approximately 136,000 ounces of gold have been produced over 11 years up to Sept 30, 2025. Annual production over the past two years from Sept 30^th, 2025, via open pit mining with crushing capacity of 2,400 tpd at Cerro Prieto Mine was 8,174 ounces of gold.

The Company recently installed a second crushing circuit which has doubled crushing capacity to over 4,200 tonnes per day which will help to facilitate our objective of significantly increasing gold production.

The Report highlights the potential of the Esperanzas Deposit area and other nearby targets. Goldgroup has commenced exploration of these areas and has, as well, begun preparations for tailings reprocessing, an important optimization initiative to further increase gold production at the mine.

The following table presents the resource NI 43-101 assessment of Measured and Indicated resources at the Esperanzas Deposit at a cut-off grade of 0.20 g/t gold. The Inferred resource estimate at the Esperanzas Deposit is below.

Please review the Report in its entirety for assumptions and detailed information pertaining to the mineral resource estimates and other important information.

About Goldgroup

Goldgroup is a Canadian-based mining Company with two high-growth gold assets in Mexico. The Company has a 100% interest in the producing Cerro Prieto heap-leach gold mine located in the State of Sonora. An optimization and exploration program is underway at Cerro Prieto to significantly increase existing production and resources.

Goldgroup is led by a team of highly successful and seasoned individuals with extensive expertise in mine development, corporate finance, and exploration in Mexico.

For further information, please contact Sophia Shane at sshane@goldgroupmining.com or +1 604 306 6867 or visit the Company’s website at www.goldgroupmining.com

On behalf of the Board of Directors

Ralph Shearing , CEO

Investors Relations
Sophia Shane
(604) 306-6867

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Certain information contained in this news release, including any information relating to future financial or operating performance, may be considered “forward-looking information” (within the meaning of applicable Canadian securities law) and “forward-looking statements” (within the meaning of the United States Private Securities Litigation Reform Act of 1995). These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Actual results could differ materially from the conclusions, forecasts and projections contained in such forward-looking information.

These forward-looking statements reflect Goldgroup’s current internal projections, expectations or beliefs and are based on information currently available to Goldgroup. In some cases forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projects”, “potential”, “scheduled”, “forecast”, “budget” or the negative of those terms or other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to materially differ from those reflected in the forward-looking information, and are developed based on assumptions about such risks, uncertainties and other factors including, without limitation: successful implementation of the Company’s plans at the Cerro Prieto project; uncertainties related to actual capital costs operating costs and expenditures; production schedules and economic returns from Goldgroup’s projects; uncertainties associated with development activities; uncertainties inherent in the estimation of mineral resources and precious metal recoveries; uncertainties related to current global economic conditions; fluctuations in precious and base metal prices; uncertainties related to the availability of future financing; potential difficulties with joint venture partners; risks that Goldgroup’s title to its property could be challenged; political and country risk; risks associated with Goldgroup being subject to government regulation; risks associated with surface rights; environmental risks; Goldgroup’s need to attract and retain qualified personnel; risks associated with potential conflicts of interest; Goldgroup’s lack of experience in overseeing the construction of a mining project; risks related to the integration of businesses and assets acquired by Goldgroup; uncertainties related to the competitiveness of the mining industry; risk associated with theft; risk of water shortages and risks associated with competition for water; uninsured risks and inadequate insurance coverage; risks associated with potential legal proceedings; risks associated with community relations; outside contractor risks; risks related to archaeological sites; foreign currency risks; risks associated with security and human rights; and risks related to the need for reclamation activities on Goldgroup’s properties, as well as the risk factors disclosed in Goldgroup’s MD&A. Any and all of the forward-looking information contained in this news release is qualified by these cautionary statements.

Although Goldgroup believes that the forward-looking information contained in this news release is based on reasonable assumptions, readers cannot be assured that actual results will be consistent with such statements. Accordingly, readers are cautioned against placing undue reliance on forward-looking information. Goldgroup expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise, except as may be required by, and in accordance with, applicable securities laws.

Qualified Persons

Preparation of the technical data in this document was supervised and approved by Rodrigo R Carneiro MSc, QP, SME Registered Member, an independent qualified person under NI 43-101.

SOURCE: Goldgroup Mining, Inc.

View the original press release on ACCESS Newswire

Boron’s inclusion on the 2025 U.S. Critical Minerals List reinforces 5E’s role as America’s next advanced-stage, domestic boron supplier

HESPERIA, CA / ACCESS Newswire / November 7, 2025 / 5E Advanced Materials, Inc. (“5E” or the “Company”) (NASDAQ:FEAM)(ASX:5EA), a U.S. development-stage company focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron derivative materials, today announced that the United States Department of the Interior has released the Final 2025 List of Critical Minerals, formally adding boron as a critical mineral vital to the U.S. economy and national security.

The U.S. Geological Survey (USGS) compiled the list, which will appear in the Federal Register on November 7, 2025, identifies 60 minerals deemed essential to national security, economic growth, and supply chain stability. Boron’s addition highlights its prominent role in energy technologies, advanced materials, defense systems, and critical infrastructure.

“The designation of boron on the U.S. Critical Minerals List marks a pivotal milestone for 5E and the nation’s supply chain,” said Paul Weibel, Chief Executive Officer of 5E Advanced Materials. “Our Fort Cady project is uniquely positioned to advance domestic production of boron, an essential input to energy technologies, defense, and high-performance manufacturing. This recognition validates the strategic importance of boron and reinforces our objective to establish 5E as a trusted U.S. supplier to rapidly expanding high-growth markets.”

The federal recognition of boron as a critical mineral creates key strategic advantages for 5E Advanced Materials and its Fort Cady operation in Southern California:

• Strategic U.S. Asset: As one of the only advanced-stage boron projects in the United States, 5E’s Fort Cady operation aligns directly with federal objectives to strengthen domestic supply chains for critical minerals and reduce dependence on foreign sources.

• Federal Program Access: Boron’s inclusion on the 2025 U.S. Critical Minerals List enhances 5E’s eligibility to engage with U.S. government funding programs, including programs administered by the U.S. Department of War Office of Strategic Capital and the U.S. International Development Finance Corporation, that support the development, processing, and refining of critical minerals. The One Big Beautiful Bill Act of 2025 authorized $5 billion for investments in critical minerals supply chains made pursuant to the Industrial Base Fund and up to $100 billion in principal amounts of direct loans and guaranteed loans for critical minerals and related industries and projects. 5E currently has a $285 million letter of interest for a potential project finance debt guarantee from the U.S. Export-Import Bank as part of the Make More in America Initiative.

• Investment and Market Positioning: The designation reinforces 5E’s standing as a strategic partner in the energy, defense, and advanced-manufacturing sectors, markets where boron’s unique chemical and thermal properties play an essential role in next-generation technologies.

• Alignment with U.S. Policy Priorities: The addition of boron underscores growing recognition of its importance to national defense, advanced materials innovation, energy independence, and the high-tech sectors, areas directly aligned with 5E’s mission and development strategy.

Together, these factors strengthen 5E’s position within the U.S. critical-materials landscape and highlight its contribution to building secure, resilient, and sustainable mineral supply chains that support national priorities.

Under the Energy Act of 2020, the USGS updates the Critical Minerals List at least every three years. The 2025 review used enhanced modeling of over 1,200 supply-disruption scenarios across 84 commodities and 402 industries, leading the Secretary of the Interior to confirm boron’s inclusion alongside copper, nickel, lithium, uranium, phosphate, and metallurgical coal.

The full text of the notice, “Final 2025 List of Critical Minerals,” is available on the Federal Register website under docket number 2025-19813 and at www.regulations.gov under docket number USGS-2025-0039.

About 5E Advanced Materials, Inc.
5E Advanced Materials, Inc. (NASDAQ:FEAM)(ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron materials, complemented by calcium-based co-products, and potentially other by-products such as lithium carbonate. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, energy independence, food, national security, and the defense sector. The Company believes factors such as government regulation and incentives focused on domestic manufacturing and supply chains and capital investments across industries will drive demand for end-use applications like solar and wind energy infrastructure, neodymium-ferro-boron magnets, defense applications, lithium-ion batteries, and other critical material applications. The business is based on the Company’s large domestic boron resource, which is located in Southern California and designated as Critical Infrastructure by the U.S. Department of Homeland Security and with the U.S. Government’s 2025 Critical Minerals List following boron’s inclusion.

Forward Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the Company’s development plans, production capabilities, commercialization strategy, offtake discussions, customer qualification processes, market demand for boron and lithium, the potential applications of its products across energy, defense, and industrial markets, and ability to access and secure any government-based financing. Any forward-looking statements are based on 5E’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the Company’s development plans, production capabilities, commercialization strategy, offtake discussions, customer qualification processes, market demand for boron and lithium, and potential applications of its products across energy, defense, and industrial markets, and ability to access and secure any government-based financing. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in 5E’s most recent Annual Report on Form 10-K and its other reports filed with the SEC. Forward-looking statements contained in this announcement are based on information available to 5E as of the date hereof and are made only as of the date of this release. 5E undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing 5E’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of 5E.

For further information contact:
Michael MacMillan or Paola Ashton
PRA Communications
team@pracommunications.com
Ph: +1 (604) 681-1407

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire